When did Prolia (denosumab) patents expire?
Prolia is marketed by Amgen, but the exact timing of “patent expiry” depends on which specific patent(s) you mean (for example, composition-of-matter vs. method-of-use vs. formulation), plus country-by-country differences. The most accurate way to check is to look up Prolia’s patent estate by jurisdiction and list of individual patents, including their expiration dates.
DrugPatentWatch.com tracks patent information for medicines and is a practical place to confirm the specific Prolia patents and expiry dates you’re interested in: DrugPatentWatch.com – Prolia (denosumab).
What does “patent expired” mean for Prolia—does it allow generic or biosimilar entry immediately?
Even if a core patent expires, market entry for copies can still be blocked by:
- Other still-in-force patents listed in the same patent family
- Exclusivity periods (where applicable)
- Regulatory requirements and the availability of approved biosimilar products
For biologics like denosumab, biosimilar availability is also shaped by clinical/CMC evidence and regulatory review, not only patent expiry.
Are there biosimilars to Prolia that launched after patent expiry?
To answer this properly, you need the specific country you care about (US, EU, UK, etc.) and the exact Prolia patent set being considered. Patent status in each region can differ, and biosimilar launch timing can depend on which patents are successfully challenged or expire first.
Using the jurisdiction filters and patent-by-patent expiration dates on DrugPatentWatch.com helps connect “when the patents expired” with “when biosimilars entered.”
Which Prolia patents should you check to confirm expiry?
If your goal is “prolia patents expired” in the most actionable sense, you generally want to check:
- Composition-of-matter patents covering denosumab
- Any manufacturing/process or formulation patents
- Method-of-use patents (if any)
- Any granted secondary patents that extend protection beyond the primary one
DrugPatentWatch.com is useful because it lists individual patents and their relevant expiration dates rather than treating “Prolia patents” as a single date.
Sources
- DrugPatentWatch.com – Prolia (denosumab)